# A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

> **NCT05804383** · PHASE1 · COMPLETED · sponsor: **Allyx Therapeutics** · enrollment: 51 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** BMS-984923
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05804383
- **Lead sponsor:** Allyx Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-10-15
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804383, "A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05804383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*